Quick Takeaways:
- Ceva Animal Health has acquired Aquilón CyL, a Spain-based biotechnology company focused on swine disease research, diagnostics, and biological solutions. Financial terms of the transaction were not disclosed.
- A key asset in the acquisition is the first and only commercial vaccine in Europe against swine dysentery caused by Brachyspira hyodysenteriae. The addition strengthens Ceva’s swine intestinal health portfolio and expands its disease prevention offering for a condition that causes significant economic losses in pig production worldwide. The vaccine also supports efforts to reduce antibiotic use in swine farming.
- Following the acquisition, Aquilón’s scientific team will join Ceva, enhancing the company’s global research and innovation capabilities in swine health. The integration is expected to support the development of new vaccines and diagnostic tools while advancing sustainable livestock production through improved disease prevention and reduced reliance on antibiotics.
Why It Matters?
Ceva is using this deal to cement a differentiated position in swine health by owning Europe’s only commercial vaccine against swine dysentery, a disease that drives major losses in pig production.
This will also deepen Ceva’s R&D pipeline and speed new swine vaccines and diagnostics to market by integrating Aquilón’s specialist scientific team into its global innovation infrastructure.
Source: Ceva
